



Monoclonal Antibody Therapies Ordering Information for Providers

In Oregon, the Delta variant of SARS-CoV-2 has caused a surge in the use of monoclonal antibody (mAb) therapies, which are now in short supply nationwide. On September 13, 2021, Oregon Health Authority’s (OHA’s) federal partner, Health and Human Services (HHS), announced mAb administration sites can no longer order mAb directly from the distributor, Amerisource Bergen. Instead, HHS determines each state’s weekly allotment of mAb, and each state subsequently identifies which sites will receive part of that allotment.

To order mAb:

- Complete this [quick registration survey](#), which will enable us to ensure that your clinic/hospital is eligible for this program.
- Complete this [COVID-19 Therapies excel spreadsheet](#) and email it to ORES8.LogisticsChiefs@dhsaha.state.or.us. Amerisource Bergen, the company that ships monoclonal antibodies, requires this step.
- If you do not have a contracted pharmacy partner, a physician or other eligible licensed provider (based on scopes of practice as determined by licensure boards for the state of Oregon) at your facility must sign an Amerisource Bergen [letter of agreement \(LOA\)](#).

Once your site completes the provider survey AND sends the completed excel spreadsheet (and the LOA if necessary) to ORES8.LogisticsChiefs@dhsaha.state.or.us, it will take 2-to-5 days to set up your account with Amerisource Bergen.

You will receive weekly emails on Mondays with a [link to request monoclonal antibodies](#). These **requests are due on Wednesdays by 11:59 pm** to be considered for the current weekly allocation. Amerisource Bergen requires a minimum order and ships in multiples, per the table below.

Product	Minimum order quantity (courses)	Administration route
Casirivimab/Imdevimab	10	IV or subcutaneously
Bamlanivimab/Etesevimab	12	IV only
Sotrovimab	6	IV only

Sites with IV capability may receive a combination of product for IV administration.

Receiving mAbs:

Due to increased demand for mAb therapy, a backlog of orders and the federal government's shift in the distribution process, Oregon sites are experiencing delays in shipment from Amerisource Bergen as well as limited quantities of casirivimab and imdevimab.

Federal allocation to the state is based on reported utilization, as well as cases and hospitalization rates. It's important every provider reports usage of mAb therapy doses.

OHA mAbs allocation process:

Oregon Health Authority (OHA) is working to equitably distribute the allocation weekly across participating providers. OHA prioritizes allocation to providers such as Federally Qualified Health Centers and Tribal Health Clinics that serve communities disproportionately impacted by COVID-19. In addition, OHA allocates monoclonal antibodies at a level proportionate to a county and region's share of statewide hospitalizations and cases over a rolling 2-week basis.

When there is greater demand than supply, OHA also utilizes [COVID-19 Community Vulnerability Index \(CCVI\) data](#) and monoclonal antibody utilization data by site to inform allocations. For example, OHA works to satisfy 100% of requests to administration sites with a high COVID-19 vulnerability score, or CCVI > 0.6. Input from local public health authorities may sometimes be used to make further refinements to our allocation decisions.

Reporting utilization of mAb doses:

Federal allocation to the state is based on utilization, as well as cases and hospitalization rates. Every provider must report usage of mAb therapy doses every **Wednesday**.

- **Hospitals** report mAb therapies as part of their overall COVID-19 utilization reporting and do not need to provide separate reports.
- **Long-term care facilities or skilled nursing facilities** report utilization through [NHSN](#) and are not required to provide separate reports.
- **Clinics and all other sites** (e.g., urgent care centers, pharmacies, etc.) must report utilization through individual HHS [TeleTracking](#) accounts.

Additional Information:

- For more information on registering and entering data into the federal reporting tracker, [click here](#).
- For technical assistance with registering, ordering or reporting, email ORES8.LogisticsChiefs@dhsosha.state.or.us.
- For more information about mAbs in Oregon, visit the [OHA mAb website](#).
- For general mAbs information, visit the Centers for Medicare & Medicaid Services [\(CMS\) mAb website](#).

Document accessibility: For individuals with disabilities or individuals who speak a language other than English, OHA can provide information in alternate formats such as translations, large print, or braille. Contact the Health Information Center at 1-971-673-2411, 711 TTY or COVID19.LanguageAccess@dhsosha.state.or.us